Honliv Healthcare Management Group Company Limited's (HKG:9906) Share Price Could Signal Some Risk

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 9x, you may consider Honliv Healthcare Management Group Company Limited (HKG:9906) as a stock to avoid entirely with its 29.2x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.

As an illustration, earnings have deteriorated at Honliv Healthcare Management Group over the last year, which is not ideal at all. One possibility is that the P/E is high because investors think the company will still do enough to outperform the broader market in the near future. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

View our latest analysis for Honliv Healthcare Management Group

pe-multiple-vs-industry
SEHK:9906 Price to Earnings Ratio vs Industry January 28th 2025
Although there are no analyst estimates available for Honliv Healthcare Management Group, take a look at this free data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.
Advertisement

How Is Honliv Healthcare Management Group's Growth Trending?

Honliv Healthcare Management Group's P/E ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the market.

Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 17%. Regardless, EPS has managed to lift by a handy 19% in aggregate from three years ago, thanks to the earlier period of growth. Accordingly, while they would have preferred to keep the run going, shareholders would be roughly satisfied with the medium-term rates of earnings growth.

This is in contrast to the rest of the market, which is expected to grow by 21% over the next year, materially higher than the company's recent medium-term annualised growth rates.

In light of this, it's alarming that Honliv Healthcare Management Group's P/E sits above the majority of other companies. It seems most investors are ignoring the fairly limited recent growth rates and are hoping for a turnaround in the company's business prospects. There's a good chance existing shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with recent growth rates.

What We Can Learn From Honliv Healthcare Management Group's P/E?

Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.

Our examination of Honliv Healthcare Management Group revealed its three-year earnings trends aren't impacting its high P/E anywhere near as much as we would have predicted, given they look worse than current market expectations. When we see weak earnings with slower than market growth, we suspect the share price is at risk of declining, sending the high P/E lower. If recent medium-term earnings trends continue, it will place shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.

Many other vital risk factors can be found on the company's balance sheet. Our free balance sheet analysis for Honliv Healthcare Management Group with six simple checks will allow you to discover any risks that could be an issue.

Of course, you might also be able to find a better stock than Honliv Healthcare Management Group. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

Valuation is complex, but we're here to simplify it.

Discover if Honliv Healthcare Management Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SEHK:9906

Honliv Healthcare Management Group

Engages in the ownership, operation, and management of hospitals in the People’s Republic of China.

Excellent balance sheet with very low risk.

Advertisement

Weekly Picks

TA
Talos
TSLA logo
Talos on Tesla ·

The "Physical AI" Monopoly – A New Industrial Revolution

Fair Value:US$665.3636.1% undervalued
22 users have followed this narrative
13 users have commented on this narrative
13 users have liked this narrative
MA
CSG logo
Marek_Trnka on CSG ·

Czechoslovak Group - is it really so hot?

Fair Value:€5547.3% undervalued
31 users have followed this narrative
1 users have commented on this narrative
13 users have liked this narrative
AL
alex30free
SECARE logo
alex30free on Swedencare ·

The Compound Effect: From Acquisition to Integration

Fair Value:SEK 46.2850.2% undervalued
8 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

AN
AnimalDoctorKwon
NOTV logo
AnimalDoctorKwon on Inotiv ·

Inotiv NAMs Test Center

Fair Value:US$1.272.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
PI
PittTheYounger
DAL logo
PittTheYounger on Delta Air Lines ·

Delta loses shine after warning of falling travel demand, but still industry leader

Fair Value:US$63.2117.8% overvalued
18 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RA
Ravedigga
ALRT logo
Ravedigga on Defence Holdings ·

Project Ixian Accelerated Rollout will Drive Valuation Expansion to £0.0150.

Fair Value:UK£0.01516.7% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OO
NEO logo
OOO97 on Neo Performance Materials ·

Undervalued Key Player in Magnets/Rare Earth

Fair Value:CA$25.3317.8% undervalued
78 users have followed this narrative
0 users have commented on this narrative
20 users have liked this narrative
DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.7% undervalued
57 users have followed this narrative
5 users have commented on this narrative
25 users have liked this narrative
BL
BlackJesus
ADBE logo
BlackJesus on Adobe ·

The Strategic Revaluation of Adobe: A Critical Analysis of Market Sentiment

Fair Value:US$46042.5% undervalued
34 users have followed this narrative
2 users have commented on this narrative
22 users have liked this narrative

Trending Discussion

Advertisement